0001209191-20-057338.txt : 20201106 0001209191-20-057338.hdr.sgml : 20201106 20201106175720 ACCESSION NUMBER: 0001209191-20-057338 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201104 FILED AS OF DATE: 20201106 DATE AS OF CHANGE: 20201106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Prout Samantha CENTRAL INDEX KEY: 0001743122 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 201295504 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER NAME: FORMER CONFORMED NAME: Prout Samantha Whiteman DATE OF NAME CHANGE: 20180607 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-04 0 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001743122 Prout Samantha C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE CRANBURY NJ 08512 0 1 0 0 Principal Accounting Officer Common Stock 2020-11-04 4 M 0 5337 14.88 A 22472 D Common Stock 2020-11-04 4 M 0 594 10.04 A 23066 D Common Stock 2020-11-04 4 S 0 5931 20.00 D 17135 D Stock Options (right to buy) 14.88 2020-11-04 4 M 0 5337 0.00 D 2028-03-26 Common Stock 5337 2940 D Stock Options (right to buy) 10.04 2020-11-04 4 M 0 594 0.00 D 2029-01-02 Common Stock 594 5148 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. As of November 4, 2020, 5,337 options were fully vested and exercisable and 2,940 remained unvested from this grant. As of November 4, 2020, 594 options were fully vested and exercisable and 5,148 remained unvested from this grant. /s/ Christian Formica, Attorney-in-Fact 2020-11-06